FIPRecover Biotechnology Co., Ltd., a leading specialist in feline antiviral pharmaceuticals, today announced a significant expansion of its manufacturing capabilities.
This strategic investment is driven by the increasing global need for accessible, high-quality treatments for Feline Infectious Peritonitis (FIP). The enhanced facility will incorporate advanced technologies to scale up the production of its core drugs, GS441524 and Molnupiravir, while further solidifying its stringent quality control protocols. “Our mission is to give every cat with FIP a fighting chance,” said a company spokesperson. “This expansion ensures we can reliably supply our clinically proven therapies to more veterinarians and pet families worldwide, without ever compromising on the safety and efficacy standards that define our products.”
Post Comment